|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Morice P, Leary A, Creutzberg C,
Abu-Rustum N and Darai E: Endometrial cancer. Lancet.
387:1094–1108. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eiriksson L, Cuartero J, Steed H, Pearcey
R, Capstick V, Schepansky A, Faught W and Dundas G: Assessment of
outcomes in surgically staged I/II endometrial adenocarcinoma
patients treated with postoperative vaginal vault radiotherapy
only. Int J Gynecol Cancer. 20:1356–1362. 2010.PubMed/NCBI
|
|
5
|
Gungorduk K, Ozdemir A, Ertas IE, Selcuk
I, Solmaz U, Ozgu E, Mat E, Gokcu M, Karadeniz T, Akbay S, et al:
Is mucinous adenocarcinoma of the endometrium a risk factor for
lymph node involvement? A multicenter case-control study. Int J
Clin Oncol. 20:782–789. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jalloul RJ, Elshaikh MA, Ali-Fehmi R,
Haley MM, Yoon J, Mahan M and Munkarah AR: Mucinous adenocarcinoma
of the endometrium: Case series and review of the literature. Int J
Gynecol Cancer. 22:812–818. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rauh-Hain JA, Vargas RJ, Clemmer J, Clark
RM, Bradford LS, Growdon WB, Goodman A, Boruta DM II, Schorge JO
and del Carmen MG: Mucinous adenocarcinoma of the endometrium
compared with endometrioid endometrial cancer: A SEER analysis. Am
J Clin Oncol. 39:43–48. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Musa F, Huang M, Adams B, Pirog E and
Holcomb K: Mucinous histology is a risk factor for nodal metastases
in endometrial cancer. Gynecol Oncol. 125:541–545. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Galic V, Schiavone MB, Herzog TJ, Holcomb
K, Lewin SN, Lu YS, Neugut AI, Hershman DL and Wright JD:
Prognostic significance of mucinous differentiation of endometrioid
adenocarcinoma of the endometrium. Cancer Invest. 31:500–504. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jackson CL, Hang S, Hansen K, He M, Sung
CJ, Quddus MR, Xiong M, Wang Y, Patel NR, Lawrence WD and Xiong J:
Endometrial adenocarcinomas with significant mucinous
differentiation: A characterization of intratumoral heterogeneity
of KRAS mutations in mucinous and endometrioid histologic
components. Int J Gynecol Cancer. 28:241–247. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sloan EA, Moskaluk CA and Mills AM:
Mucinous differentiation with tumor infiltrating lymphocytes is a
feature of sporadically methylated endometrial carcinomas. Int J
Gynecol Pathol. 36:205–216. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lax SF: Pathology of endometrial
carcinoma. Adv Exp Med Biol. 943:75–96. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fadare O, Roma AA, Mhawech-Fauceglia P,
Parkash V and Rabban JT: The diagnosis of mucinous lesions in
endometrial samplings by gynaecological pathologists: An analysis
of diagnostic reproducibility. Pathology. 50:276–285. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jones NL, Xiu J, Chatterjee-Paer S,
Buckley de Meritens A, Burke WM, Tergas AI, Wright JD and Hou JY:
Distinct molecular landscapes between endometrioid and
nonendometrioid uterine carcinomas. Int J Cancer. 140:1396–1404.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee S, Sahasrabuddhe VV, Mendoza-Cervantes
D, Zhao R and Duggan MA: Tissue-based immunohistochemical biomarker
expression in malignant glandular lesions of the uterine cervix: A
systematic review. Int J Gynecol Pathol. 37:128–140. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stampoliou A, Arapantoni-Dadioti P and
Pavlakis K: Epigenetic mechanisms in endometrial cancer. J BUON.
21:301–306. 2016.PubMed/NCBI
|
|
17
|
Zhou JY, Zhang L, Wei LH and Wang JL:
Endometrial carcinoma-related genetic factors: Application to
research and clinical practice in China. BJOG. 123 (Suppl
3):S90–S96. 2016. View Article : Google Scholar
|
|
18
|
Banno K, Yanokura M, Iida M, Masuda K and
Aoki D: Carcinogenic mechanisms of endometrial cancer: Involvement
of genetics and epigenetics. J Obstet Gynaecol Res. 40:1957–1967.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Men C, Chai H, Song X, Li Y, Du H and Ren
Q: Identification of DNA methylation associated gene signatures in
endometrial cancer via integrated analysis of DNA methylation and
gene expression systematically. J Gynecol Oncol. 28:e832017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Caplakova V, Babusikova E, Blahovcova E,
Balharek T, Zelieskova M and Hatok J: DNA methylation machinery in
the endometrium and endometrial cancer. Anticancer Res.
36:4407–4420. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Romanek-Piva K, Gałczyński K,
Adamiak-Godlewska A, Rechberger T and Postawski K: DNA methylation
and DNA methyltransferase (DNMT1) activity pattern in endometrial
carcinoma. Ginekol Pol. 87:6–10. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fialkova V, Vidomanova E, Balharek T,
Marcinek J, Kudela E, Hanysova S, Visnovsky J, Dobrota D and Hatok
J: DNA methylation as mechanism of apoptotic resistance development
in endometrial cancer patients. Gen Physiol Biophys. 36:521–529.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bartosch C, Lopes JM and Jeronimo C:
Epigenetics in endometrial carcinogenesis-part 1: DNA methylation.
Epigenomics. 9:737–755. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lai HC, Wang YC, Yu MH, Huang RL, Yuan CC,
Chen KJ, Wu CC, Chiang KJ and Chao TK: DNA methylation as a
biomarker for the detection of hidden carcinoma in endometrial
atypical hyperplasia. Gynecol Oncol. 135:552–559. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pan Y, Liu G, Zhou F, Su B and Li Y: DNA
methylation profiles in cancer diagnosis and therapeutics. Clin Exp
Med. 18:1–14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang T, Qiu H, Bao W, Li B, Lu C, Du G,
Luo X, Wang L and Wan X: Epigenetic inactivation of EFEMP1 is
associated with tumor suppressive function in endometrial
carcinoma. PLoS One. 8:e674582013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fiolka R, Zubor P, Janusicova V, Visnovsky
J, Mendelova A, Kajo K, Lasabova Z, Plank L and Danko J: Promoter
hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and
CDH1 in endometrial cancer. Oncol Rep. 30:2878–2886. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sheng Y, Wang H, Liu D and Zhang C, Deng
Y, Yang F, Zhang T and Zhang C: Methylation of tumor suppressor
gene CDH13 and SHP1 promoters and their epigenetic regulation by
the UHRF1/PRMT5 complex in endometrial carcinoma. Gynecol Oncol.
140:145–151. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen YC, Tsao CM, Kuo CC, Yu MH, Lin YW,
Yang CY, Li HJ, Yan MD, Wang TJ, Chou YC and Su HY: Quantitative
DNA methylation analysis of selected genes in endometrial
carcinogenesis. Taiwan J Obstet Gynecol. 54:572–579. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang RL, Su PH, Liao YP, Wu TI, Hsu YT,
Lin WY, Wang HC, Weng YC, Ou YC, Huang TH and Lai HC: Integrated
epigenomics analysis reveals a DNA methylation panel for
endometrial cancer detection using cervical scrapings. Clin Cancer
Res. 23:263–272. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen H, Zhang C, Sheng Y, Yao S, Liu Z,
Zhang C and Zhang T: Frequent SOCS3 and 3OST2 promoter methylation
and their epigenetic regulation in endometrial carcinoma. Am J
Cancer Res. 5:180–190. 2015.PubMed/NCBI
|
|
32
|
Guo Y, Peng Y, Gao D, Zhang M, Yang W,
Linghu E, Herman JG, Fuks F, Dong G and Guo M: Silencing HOXD10 by
promoter region hypermethylation activates ERK signaling in
hepatocellular carcinoma. Clin Epigenetics. 9:1162017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yuan YH, Wang HY, Lai Y, Zhong W, Liang
WL, Yan FD, Yu Z, Chen JK and Lin Y: Epigenetic inactivation of
HOXD10 is associated with human colon cancer via inhibiting the
RHOC/AKT/MAPK signaling pathway. Cell Commun Signal. 17:92019.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang LH, Choi YL, Hua XY, Shin YK, Song
YJ, Youn SJ, Yun HY, Park SM, Kim WJ, Kim HJ, et al: Increased
expression of sonic hedgehog and altered methylation of its
promoter region in gastric cancer and its related lesions. Mod
Pathol. 19:675–683. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Brinkhuizen T, van den Hurk K,
Winnepenninckx VJ, de Hoon JP, van Marion AM, Veeck J, van Engeland
M and van Steensel MA: Epigenetic changes in basal cell carcinoma
affect SHH and WNT signaling components. PLoS One. 7:e517102012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fan Y, Wang Y, Fu S, Liu D and Lin S:
Methylation-regulated ZNF545 inhibits growth of the p53-mutant
KYSE150 cell line by inducing p21 and Bax. Exp Ther Med.
18:1563–1570. 2019.PubMed/NCBI
|
|
37
|
Xiang S, Xiang T, Xiao Q, Li Y, Shao B and
Luo T: Zinc-finger protein 545 is inactivated due to promoter
methylation and functions as a tumor suppressor through the
Wnt/β-catenin, PI3K/AKT and MAPK/ERK signaling pathways in
colorectal cancer. Int J Oncol. 51:801–811. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lin YL, Wang YP, Li HZ and Zhang X:
Aberrant promoter methylation of PCDH17 (Protocadherin 17) in serum
and its clinical significance in renal cell carcinoma. Med Sci
Monit. 23:3318–3323. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Uyen TN, Sakashita K, Al-Kzayer LF,
Nakazawa Y, Kurata T and Koike K: Aberrant methylation of
protocadherin 17 and its prognostic value in pediatric acute
lymphoblastic leukemia. Pediatr Blood Cancer. 64:2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Musialik E, Bujko M, Kober P, Grygorowicz
MA, Libura M, Przestrzelska M, Juszczyński P, Borg K, Florek I,
Jakóbczyk M and Siedlecki JA: Promoter DNA methylation and
expression levels of HOXA4, HOXA5 and MEIS1 in acute myeloid
leukemia. Mol Med Rep. 11:3948–3954. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kurman RJ, Carcangiu ML, Herrington CS and
Young RH: WHO classification of tumours of female reproductive
organs. International Agency for Research on Cancer. 307:2014.
|
|
42
|
Akhavan-Niaki H and Samadani AA: DNA
methylation and cancer development: Molecular mechanism. Cell
Biochem Biophys. 67:501–513. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ding WJ, Yang Y, Chen ZX, Wang YY, Dong
WL, Cen JN, Qi XF, Jiang F and Chen SN: Methylation level of
Rap1GAP and the clinical significance in MDS. Oncol Lett.
16:7287–7294. 2018.PubMed/NCBI
|
|
44
|
Kim DS, Lee WK and Park JY: Promoter
methylation of Wrap53α, an antisense transcript of p53, is
associated with the poor prognosis of patients with non-small cell
lung cancer. Oncol Lett. 16:5823–5828. 2018.PubMed/NCBI
|
|
45
|
Jones A, Teschendorff AE, Li Q, Hayward
JD, Kannan A, Mould T, West J, Zikan M, Cibula D, Fiegl H, et al:
Role of DNA methylation and epigenetic silencing of HAND2 in
endometrial cancer development. PLoS Med. 10:e10015512013.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Meršaková S, Holubeková V, Grendár M,
Višňovský J, Ňachajová M, Kalman M, Kúdela E, Žúbor P, Bielik T,
Lasabová Z and Danko J: Methylation of CADM1 and MAL together with
HPV status in cytological cervical specimens serves an important
role in the progression of cervical intraepithelial neoplasia.
Oncol Lett. 16:7166–7174. 2018.PubMed/NCBI
|
|
47
|
Abbasi AA: Diversification of four human
HOX gene clusters by step-wise evolution rather than ancient
whole-genome duplications. Dev Genes Evol. 225:353–357. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Seifert A, Werheid DF, Knapp SM and
Tobiasch E: Role of Hox genes in stem cell differentiation. World J
Stem Cells. 7:583–595. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bhatlekar S, Fields JZ and Boman BM: HOX
genes and their role in the development of human cancers. J Mol Med
(Berl). 92:811–823. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Javed S and Langley SE: Importance of HOX
genes in normal prostate gland formation, prostate cancer
development and its early detection. BJU Int. 113:535–540. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chekmareva M, Ellenson LH and Pirog EC:
Immunohistochemical differences between mucinous and microglandular
adenocarcinomas of the endometrium and benign endocervical
epithelium. Int J Gynecol Pathol. 27:547–554. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Vardhini NV, Rao PJ, Murthy PB and
Sudhakar G: HOXD10 expression in human breast cancer. Tumour Biol.
35:10855–10860. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang L, Chen S, Xue M, Zhong J, Wang X,
Gan L, Lam EK, Liu X, Zhang J, Zhou T, et al: Homeobox D10 gene, a
candidate tumor suppressor, is downregulated through promoter
hypermethylation and associated with gastric carcinogenesis. Mol
Med. 18:389–400. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yang H, Zhou J, Mi J, Ma K, Fan Y, Ning J,
Wang C, Wei X, Zhao H and Li E: HOXD10 acts as a tumor-suppressive
factor via inhibition of the RHOC/AKT/MAPK pathway in human
cholangiocellular carcinoma. Oncol Rep. 34:1681–1691. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Joo MK, Park JJ and Chun HJ: Impact of
homeobox genes in gastrointestinal cancer. World J Gastroenterol.
22:8247–8256. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Myers C, Charboneau A, Cheung I, Hanks D
and Boudreau N: Sustained expression of homeobox d10 inhibits
angiogenesis. Am J Pathol. 161:2099–2109. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wang Y, Li Z, Zhao X, Zuo X and Peng Z:
miR-10b promotes invasion by targeting HOXD10 in colorectal cancer.
Oncol Lett. 12:488–494. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Carrio M, Arderiu G, Myers C and Boudreau
NJ: Homeobox D10 induces phenotypic reversion of breast tumor cells
in a three-dimensional culture model. Cancer Res. 65:7177–7185.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Cao YM, Gu J, Zhang YS, Wei WJ, Qu N, Wen
D, Liao T, Shi RL, Zhang L, Ji QH, et al: Aberrant hypermethylation
of the HOXD10 gene in papillary thyroid cancer with BRAFV600E
mutation. Oncol Rep. 39:338–348. 2018.PubMed/NCBI
|
|
60
|
Ma L, Teruya-Feldstein J and Weinberg RA:
Tumour invasion and metastasis initiated by microRNA-10b in breast
cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Li S, Zhang J, Zhao Y, Wang F, Chen Y and
Fei X: miR-224 enhances invasion and metastasis by targeting HOXD10
in non-small cell lung cancer cells. Oncol Lett. 15:7069–7075.
2018.PubMed/NCBI
|
|
62
|
Yachi K, Tsuda M, Kohsaka S, Wang L, Oda
Y, Tanikawa S, Ohba Y and Tanaka S: miR-23a promotes invasion of
glioblastoma via HOXD10-regulated glial-mesenchymal transition.
Signal Transduct Target Ther. 3:332018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zeng Z, Liu S, Cai J, Li Z, Wu H, Chen H
and Huang Y: miR-501 promotes hemangioma progression by targeting
HOXD10. Am J Transl Res. 11:2439–2446. 2019.PubMed/NCBI
|
|
64
|
Li C, Huo B, Wang Y and Cheng C:
Downregulation of microRNA-92b-3p suppresses proliferation,
migration, and invasion of gastric cancer SGC-7901 cells by
targeting Homeobox D10. J Cell Biochem. 120:17405–17412. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
An N, Luo X, Zhang M and Yu R:
MicroRNA-376b promotes breast cancer metastasis by targeting Hoxd10
directly. Exp Ther Med. 13:79–84. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Rinn JL, Kertesz M, Wang JK, Squazzo SL,
Xu X, Brugmann SA, Goodnough LH, Helms JA, Farnham PJ, Segal E and
Chang HY: Functional demarcation of active and silent chromatin
domains in human HOX loci by noncoding RNAs. Cell. 129:1311–1323.
2007. View Article : Google Scholar : PubMed/NCBI
|
